Hair Loss

Acute-onset madarosis following MMR vaccination.

No abstract available

PMID 19343978

#Hair #Loss #MMR #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/19343978/

Alopecia Areata After Vaccination: Recurrence with Rechallenge.

“Alopecia areata (AA) is the most common form of hair loss in children. We report the case of a child who had two episodes of AA after two different vaccines with complete hair regrowth between the episodes. This case supports the concept that vaccination might be a trigger for the development of AA in genetically predisposed children.”

#Hair #Loss #Alopecia #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/27071855/

[Alopecia universalis in an adult after routine tetanus toxoid vaccine].

No abstract available

PMID 20451934

#Hair #Loss #Alopecia #Tetanus #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/20451934/

A case-control study of quadrivalent human papillomavirus vaccine-associated autoimmune adverse events.

“It was observed that cases with the SAAE outcomes of gastroenteritis (odds ratio (OR) = 4.6, 95% confidence interval (CI) = 1.3-18.5), arthritis (OR = 2.5, 95% CI = 1.4-4.3), systemic lupus erythematosus (OR = 5.3, 95% CI = 1.5-20.5), vasculitis (OR = 4, 95% CI = 1.01-16.4), alopecia (OR = 8.3, 95% CI = 4.5-15.9), or CNS conditions (OR = 1.8, 95% CI = 1.04-2.9) were significantly more likely than controls to have received HPV4 vaccine (median onset of SAAE symptoms from 6 to 55 days post-HPV4 vaccination).”

#Gardasil #Lupus #Arthritis #Autoimmunity #HPV #Hair #Loss
#Gastrointestinal #Alopecia #Neurological #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/25535199/

Hair loss after routine immunizations.

“A total of 60 evaluable reports submitted since 1984 and coded for “alopecia” after immunizations included 16 with positive rechallenge (hair loss after vaccination on more than 1 occasion), 4 of which were definite and 12 possible or probable. Of the 60 cases, 46 had received hepatitis B vaccines. Both of the currently available recombinant products, as well as the former plasma-derived product, were represented. Females predominated in all age groups. The majority of patients recovered, but clinical features, such as intervals from vaccination until onset and the extent and reversibility of hair loss, varied widely. Nine patients reported previous medication allergy.”

#Hair #Loss #Alopecia #Hepatitis B #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/9326478/

Recombinant Human Hepatitis B Vaccine Initiating Alopecia Areata: Testing the Hypothesis Using the C3H/HeJ Mouse Model

#Alopecia #Hair #Loss #Hepatitis B #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956183/

Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of Adverse Events in a National Database.

“Our study showed no significantly increased risks of severe autoimmune adverse events, except arthritis and alopecia, after vaccination.”

#Hair #Loss #Arthritis #Alopecia #Shingles #Herpes #Zoster #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/26151783/

? Telogen effluvium following bivalent human papillomavirus vaccine administration: a report of two cases.

“We describe two cases of telogen effluvium occurring in two 11-year-old children following bivalent human papillomavirus (HPV) vaccine administration. The two children began to lose their hair following the second HPV vaccine dose. Alopecia worsened following the third vaccine dose and then resolved spontaneously within a few months. In both cases, laboratory analysis and psychiatric evaluation excluded causes other than anti-HPV vaccine. Social discomfort and isolation were associated with alopecia in the two children. The clinical presentation was consistent with a pattern of telogen effluvium. The identification of specific vaccine components responsible for triggering the adverse event remains difficult. In similar cases, suspension of immunization is not recommended, as it provides health benefits that overcome the possible adverse effect of transient telogen effluvium. Caregivers should ensure psychiatric support to their patients to manage the social and emotional distress that might be associated with hair loss.”

#Gardasil #Hair #Loss #Alopecia
#HPV #Vaccine #MedScienceResearch

https://www.ncbi.nlm.nih.gov/m/pubmed/22584489/